The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).
Michael Roger Harrison
Honoraria - Novartis
Research Funding - Pfizer
Daniel J. George
Consultant or Advisory Role - Astellas Pharma; Bayer; Genentech; Novartis; Pfizer
Honoraria - Genentech; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Mark S. Walker
No relevant relationships to disclose
Lori L. Hudson
Research Funding - Pfizer
Connie Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Beata Korytowsky
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Edward J. Stepanski
No relevant relationships to disclose
Amy P. Abernethy
Consultant or Advisory Role - Amgen; Helsinn Therapeutics; Novartis
Research Funding - Alexion Pharmaceuticals; Amgen; BioVex; Bristol-Myers Squibb; DARA BioSciences; Helsinn Therapeutics; Kanglaite Pharmaceutical ; Lilly; Mi-Co; Novartis; Pfizer